Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Immunol
Huvudupphovsmän: Georgescu, Maria T., Moorehead, Paul C., Liu, Tongyao, Dumont, Jennifer, Scott, David W., Hough, Christine, Lillicrap, David
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2020
Ämnen:
Immunology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025534/
https://ncbi.nlm.nih.gov/pubmed/32117285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00138
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk